Crestor Breaking News

The following Crestor news articles are about Crestor, the recent misleading Crestor ad, and other commentary and information from news sources across the country and around the world. If you have suffered due to Crestor use, fill out this simple form for a free Crestor case evaluation.

Statins may reduce heart disease - LDL even worse than thought

March 26, 2006 (fortwayne.com)

Crestor is considered the most potent of several statins on the market, but it has been dogged by worries relating to kidney and muscle-pain side effects, and it has made little headway in the market against such rivals as Pfizer Inc.’s Lipitor, the world’s biggest-selling drug, and Merck & Co.’s Zocor

Maker of Crestor revises warning label for its controversial cholesterol medication but consumer groups are not satisfied

August 8th, 2005 (24-7pressrelease.com)

Crestor (rosuvastatin calcium) claims to lower the amount of total cholesterol in the bloodstream, including LDL cholesterol and triglycerides. After several reports of negative side effects including death from Crestor users, the FDA issued an alert and asked the drug's manufacturer, AstraZeneca, to revise the warning label.

The Crestor warning label now states that "unexplained muscle pain and weakness could be a sign of a rare but serious side effect and should be reported to your doctor right away." The FDA and AstraZeneca warn against use of Crestor for consumers with liver or kidney problems, Chinese or Japanese decent, pregnant or nursing, or in combination with alcohol use or certain prescription medicines.

AstraZeneca chief facing shareholder pressure to waive bonus

January 23, 2005 (www.turkishpress.com)

The performance of cholesterol-busting drug Crestor was meanwhile also set to come under scrutiny after an employee of the US Food and Drug Administration (FDA) said further tests were required, although this did not reflect the views of the FDA itself.

Drug firm lowers sales forecasts

January 23, 2005 (www.timesonline.co.uk)

ASTRA ZENECA, the pharmaceutical group that has endured a difficult four months, is expected next week to lower hopes for the future sales of Crestor, the cholesterol-lowering drug once seen as a potential $5 billion-a-year (€3.8 billion) blockbuster.

Cholesterol Drug Linked to a Death

January 11, 2005 (nytimes.com)

Crestor, a cholesterol-lowering drug from AstraZeneca, has been linked to the death of a patient, the company said on Monday. The death, possibly caused by rhabdomyolysis, a severe muscle-wasting condition, has been reported to regulators worldwide, a company spokesman, Steve Brown, said.

Is drug-maker's word good enough to go on?

Consumers face decision between believing company or advocacy group

December 27, 2004 (theolympian.com)

Crestor maker AstraZeneca says reports of adverse reactions to the drug are comparable to other cholesterol drugs. Advocacy group Public Citizen says those same reports show the drug has a higher-than-average rate of problems.

FDA requires Crestor ads be pulled

December 23, 2004 (boston.com/business)

"Newspaper advertising by a manufacturer that defended the cholesterol-lowering drug Crestor made "false or misleading safety claims," the government said in a letter released yesterday that requires the ads to be pulled."

Fannie Mae's Christmas Cheer

December 23, 2004 (news.ft.com)

"In the high-energy world of US drug advertising, AstraZeneca's Crestor anti-cholesterol pill is a serious contender. The company regularly bombards television viewers with commercials showing male and female patients who have triumphed over high cholesterol to achieve a Crestor-assisted state of health. The warnings on possible risks are disposed of with the speed of a heart attack."

Cholesterol drug ads called false, misleading

December 23, 2004 (mercurynews.com)

"AstraZeneca's recent full-page newspaper advertisements defending the safety of its cholesterol-lowering pill, Crestor, are "false and misleading,'' in part because serious concerns remain about the safety of the drug, federal drug regulators said Wednesday."

NIH Scientists Said to Have Taken Payouts from Biomedical Companies

December 22, 2004 (npr.org)

AstraZeneca To Overhaul Clinical Processes

December 22, 2004 (pubs.asc.org)

"The move also follows FDA rejection of the company’s blood-thinning drug, Exanta (ximelagatran), in October, and questions regarding the safety of Crestor (rosuvastatin), the company’s cholesterol-lowering drug, that surfaced during congressional hearings last month."

FDA: Crestor falsely playing down its risks

December 22, 2004 (dallasnews.com)

"The agency is looking at an ad for Crestor. It mentions that the drug could cause liver damage but then says that FDA scientists have dismissed such concerns.
In actuality, the FDA says it made the opposite conclusion, writing that it's had concerns about Crestor since the day it was approved. Crestor currently includes warnings on its label about possible liver damage or failure."

AstraZeneca Relies on Crestor After Iressa Setback

December 20, 2004 (bloomberg.com)

"On Dec. 7, Mike Rance, vice president of corporate affairs at AstraZeneca, said Crestor sales had been hurt by safety questions raised by U.S. Food and Drug Administration official David Graham. Sales have improved since then, McKillop said Dec. 17."

What you need to know about these prescriptions

December 20, 2004 (dallasnews.com)

"Risks: Kidney failure and rhabdomyolysis, a rare but potentially fatal muscle disease. Complications are more likely at higher doses (the highest approved dose is 40 milligrams)."

Anti-cholesterol drug Crestor should be banned, says drug safety advocate Dr. Sidney Wolfe

December 20, 2004 (newstarget.com)

"Consumer advocate Dr. Sidney Wolfe renewed his effort Friday to get the anti-cholesterol drug Crestor removed from sale."

Crestor ads draw fire; FDA could act

December 8, 2004 (usatoday.com)

"Crestor is one of five drugs named as potentially hazardous by FDA drug safety officer David Graham in testimony to Congress. AstraZeneca, which manufactures and markets Crestor, responded with full-page advertisements in national and regional publications, including The Wall Street Journal, The Washington Post,The New York Times, and USA TODAY that said, "The FDA has confidence in the safety and efficacy of CRESTOR.""

U.S. group says Crestor ads 'misleading'

November 25, 2004 (reuters.co.uk)

"It is the only cholesterol lowering drug ... that causes acute renal failure," and a higher risk of a rare muscular disease, Graham, the associate director for science in the Office of Drug Safety, testified on November 18."

AstraZeneca Defends Crestor

November 23, 2004 (thestreet.com)

"AstraZeneca has been the subject of frequent criticism by the Public Citizen Health Research Group, which has called on the FDA to ban Crestor, alleging that the drug has been linked to an unacceptable rate of side effects. The company has repeatedly defended itself against the group's claims."

Lack of data stopped Crestor study

November 23, 2004 (guardian.co.uk)

"Dr David Graham, an associate director of US regulator the food and drug administration, last week left the drugs industry reeling when he questioned the safety of five drugs, including Crestor and GlaxoSmithKline's Serevent."

Advocate Suggests Crestor May Harm Kidneys

October 29, 2004 (abcnews.go.com)

"Data provided by AstraZeneca indicated that kidney failure made up 3.5 percent of adverse events for Crestor known by the generic name rosuvastatin compared to 5.7 percent for lovastatin, 4.0 percent for simvastatin and fluvastatin, 3.0 percent for pravastatin and 2.2 percent for atorvastatin."

Weitz & Luxenberg is no longer accepting new Crestor cases.

see also:

Breaking News Crestor Drug Research: Breaking Crestor News
Crestor Breaking News: Learn more about Crestor its harmful effects

News & Warnings Crestor News - Get the latest News on AstraZeneca's dangerous cholesterol drug
The Crestor News you need to stay on top of this developing situation.